Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review

Executive Summary

Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US

You may also be interested in...



Sanofi Xyzal OTC Antihistamine Claims Lose Second Challenge In Six Months

Sanofi will modify claims in social media ads that its Xyzal Allergy 24HR antihistamine is 'twice as fast' as Bayer's s Claritin after the US National Advertising Division found the statement is not supported by head-to-head testing. NAD also recommended the firm discontinue the claim the product provides “relief that starts at hour 1 instead of hour 2.”

Sanofi Xyzal OTC Antihistamine Claims Lose Second Challenge In Six Months

Sanofi will modify claims in social media ads that its Xyzal Allergy 24HR antihistamine is 'twice as fast' as Bayer's s Claritin after the US National Advertising Division found the statement is not supported by head-to-head testing. NAD also recommended the firm discontinue the claim the product provides “relief that starts at hour 1 instead of hour 2.”

Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine

FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS122419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel